Search

Displaying results 2891 - 2900 of 7687 in total
  1. Drug

    Veligrotug

    go.drugbank.com/drugs/DB18976
    Approved

    [L63929] The FDA approved veligrotug-vvze on June 26, 2026, for the treatment of thyroid eye disease regardless of disease activity or duration.[L63798,L63929]

  2. Drug

    Turoctocog alfa

    go.drugbank.com/drugs/DB09109
    Approved

    [A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]

    Products: NOVOEİGHT 250 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, NOVOEİGHT 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET
  3. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999.

  4. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

  5. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    GAA to the lysosome, where it can perform its normal function. … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  6. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

  7. Drug

    Lomustine

    go.drugbank.com/drugs/DB01206
    ApprovedInvestigational

    An alkylating agent of value against both hematologic malignancies and solid tumors.

  8. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] The FDA granted vusolimogene oderparepvec-wtpg accelerated approval on August 6, 2026, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed … cells, causing tumor lysis and release of tumor and viral antigens, with the GALV-GP-R– glycoprotein enhancing direct tumor killing and GM-CSF promoting dendritic cell and monocyte activation to drive an

  9. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … [L31443,L31473] It is the first oral MET-targeted tyrosine kinase inhibitor to allow for once-daily dosing,[L31473] an advantage that may aid in easing the pill burden often associated with chemotherapeutic

  10. Drug

    Flosequinan

    go.drugbank.com/drugs/DB13228
    ApprovedWithdrawn

    Flosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]